Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
University of British Columbia
$25,000.00
Therapeutic interventions that alter colitogenic microbiota
FY 2018-19
Summary
Inflammatory bowel disease (IBD) is a major global health burden and the rapid surge in pediatric cases in Canada over the past decade is raising alarm bells. Current pharmaceutical therapies are risky or ineffective, cost and health-wise, especially for long-term use and are associated with severe side effects. Therefore, new alternative therapies for IBD are needed urgently. Probiotic therapy, which is the ingestion of non-pathogenic microorganisms to provide health benefits, is considered a potential treatment option. However, clinical trials using probiotics for IBD treatment have yielded very inconsistent and difficult to interpret data. Specific to IBD, the gut environment is highly inflamed and oxidized; these properties may interfere with the growth and therefore beneficial effects of probiotics. As such, current probiotics are ineffective at persisting in the hostile gut of IBD patients. A novel therapeutic approach is to engineer designer probiotics that strategically target these limitations. The present invention relates to bioavailable and optimized genetically-engineered recombinant probiotic bacteria with enhanced therapeutic potential, for use in treating IBD. Here we propose that our novel patented next generation microbiome-based technologies is an alternative to traditional probiotics to enhance bioavailability and is a potential alternative therapeutic option for IBD. This proposal aims to test how the designer probiotics enrich gut health in pre-clinical models and safety trials in humans. Our team includes experts on: colitis, Crohn's disease, gut microbiome, gut immunity, metabolism, neuroinflammation, glycochemistry, large animals, pharmaceuticals development, marketing and commercialization, and sex and gender determinants for health research.
Department
Program
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
398937
Name
Gibson Deanna L
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
Therapeutic interventions that alter colitogenic microbiota
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Bio Engineered Probiotics; Colonization And Persistence; Commercialization; Drug Development; Enteric Microbes; Gut Microbiome; Inflammatory Bowel Disease; Microbiome-Based Therapeutics; Mucosal Healing; Next Generation Beneficial Microbes
Abstract
Inflammatory bowel disease (IBD) is a major global health burden and the rapid surge in pediatric cases in Canada over the past decade is raising alarm bells. Current pharmaceutical therapies are risky or ineffective, cost and health-wise, especially for long-term use and are associated with severe side effects. Therefore, new alternative therapies for IBD are needed urgently. Probiotic therapy, which is the ingestion of non-pathogenic microorganisms to provide health benefits, is considered a potential treatment option. However, clinical trials using probiotics for IBD treatment have yielded very inconsistent and difficult to interpret data. Specific to IBD, the gut environment is highly inflamed and oxidized; these properties may interfere with the growth and therefore beneficial effects of probiotics. As such, current probiotics are ineffective at persisting in the hostile gut of IBD patients. A novel therapeutic approach is to engineer designer probiotics that strategically target these limitations. The present invention relates to bioavailable and optimized genetically-engineered recombinant probiotic bacteria with enhanced therapeutic potential, for use in treating IBD. Here we propose that our novel patented next generation microbiome-based technologies is an alternative to traditional probiotics to enhance bioavailability and is a potential alternative therapeutic option for IBD. This proposal aims to test how the designer probiotics enrich gut health in pre-clinical models and safety trials in humans. Our team includes experts on: colitis, Crohn's disease, gut microbiome, gut immunity, metabolism, neuroinflammation, glycochemistry, large animals, pharmaceuticals development, marketing and commercialization, and sex and gender determinants for health research.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gibson, Deanna L; Frohlick, Susan E; Ghosh, Sanjoy; Morck, Douglas W; Sly, Laura M; Zandberg, Wesley F
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $25,000~ $0~